Home / Europe / Germany / Life Sciences & Healthcare

Life Sciences & Healthcare

The CMS Life Sciences und Healthcare Sector Group is made up of over 480 lawyers across Europe, many of whom have specialised in the Life Sciences und Healthcare industry for several years.

The essence of the group's approach is teamwork, working closely as colleagues in Western and Central Europe. The group has complementary expertise in pharmaceutical, biotechnology, medical device, diagnostic and related areas, so can offer pan-European and local, national advice and assistance to the Life Sciences und Healthcare industries.

The group is recognised as having centres of excellence in respect of pharmaceuticals and medical devices in its practices in the United Kingdom, the Netherlands and Germany as well as specialist tax expertise in France.

Services

The CMS Life Sciences und Healthcare Sector Group provides the following comprehensive range of services:

  • Regulatory
  • Pre-clinical and clinical research
  • Collaboration and licensing
  • Financing/M&A stock option schemes
  • Business restructuring
  • Strategic alliances, mergers and acquisitions
  • Distribution and parallel import issues
  • Patent protection and enforcement
  • Branding, trade dress, advertising and labelling
  • Media issues
  • Personal data
  • Product liability and litigation
  • Health and safety
  • EC & competition/competition enforcement
  • Public sector tendering
  • Environment
  • Immigration

Contact

For further information on CMS Life Sciences und Healthcare Sector Group please contact Mr. Jens Wagner.

We are strategic partners of

Young Excellence in healthcare

Young Excellence in Healthcare (YEH) is an interdisciplinary network bringing together young professionals from the healthcare sector. It seeks to develop an intelligent framework for delivering health services in the world of tomorrow. CMS Germany advises YEH strategically and exclusively on all legal matters. CMS also acts as a sounding board for the legal issues and healthcare policies YEH wishes to promote.

Law Firm of the Year for Healthcare

JUVE Guide, 2018/2019

Choose area

Lifesciences & Healthcare
Care Market
As the population in Germany ages, care and retirement homes are one of the fastest-growing sectors in the country. As such, they are attracting incre
Lifesciences & Healthcare
Healthcare
The healthcare sector in Germany is heavily regulated, shaped by a number of very different interests and, above all, subject to constant change. Demo
03/01/2024
CMS Life Sciences & Healthcare Global Brochure
With big deals fuelling record levels of M&A activity, a steady stream of innovative and disruptive technologies, new and increasingly complex regulatory challenges and a thriving start-up community...

Feed

28/02/2024
CMS advises Bruker on the multi-jur­is­dic­tion­al acquisition of ELITech,...
Frankfurt/Main – Bruker has agreed to acquire ELITechGroup, a provider of specialty in vitro diagnostic (IVD) systems, from TecFin S.à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm, for EUR 870 million in cash, excluding the carved out ELITech clinical chemistry business. The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals and other customary closing conditions.A team of CMS Germany headed by lead partner Dr Hendrik Hirsch acted as lead transaction counsel on this landmark transaction for Bruker's MDx business covering all M&A aspects of the transaction, IVDR and other regulatory aspects, antitrust and FDI filings, the carve out of the clinical chemistry business and support on the employee consultation processes in France and the Netherlands. ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products. Its molecular diagnostic business accounts for the majority of the to-be-acquired revenues and provides the unique sample-to-answer (S2A) instruments InGenius® and Be-Genius® in the mid-to-high throughput MDx category with PCR diagnostic assays for infections and diseases. ELITechGroup, excluding the clinical chemistry business, achieved approximately EUR 150 million in revenues in 2023. ELITechGroup generates the majority of its revenues from Europe, with significant business also in North and Latin America. Its major R&D and production sites are in Italy, the United States, France and Germany. CMS Germany Dr Hendrik Hirsch, Partner, Co-Lead Dr Jacob Siebert, Partner, Co-Lead Dr Dirk Baukholt, Principal Counsel Dr Berrit Roth-Mingram, Counsel Dr Maximilian Stark, Senior Associate, all Corporate/M&A Dr Roland Wiring, Partner Lukas Burgdorff, Associate Noah Rodenkirchen, Associate, all Regulatory & Lifesciences Dr Thomas Hirse, Part­ner Se­basti­an Vautz, Senior Associate Lisa Dietrich, Associate, all IP Dr Michael Bauer, Partner Stefan Lehr, Partner Kai Neuhaus, Partner Moritz Pottek, Counsel Dr. Denis Schlimpert, Counsel Kirsten Baubkus-Gerard, Senior Associate David Rappenglück, As­so­ci­ate Be­ne­dikt Christian Voss, Associate, all Antitrust, Competition & Trade Dr Thomas de la Motte, Partner Dr Markus Pfaff, Partner Dr André Frischemeier, Partner Hatice Aykel, Counsel Alisa Brehm, Senior Associate Thomas Schaak, Senior Associate Dr Sait Dogan, Associate, all Banking & Finance  Dr André Lippert, Part­ner Con­stan­ze Schweidtmann, Associate, both Real Estate & Public Dr Boris Alles, Partner Dr Theresa Kipp, Senior Associate, both Labor, Employment & Pensions CMS France Benoît Gomel, Partner Vincent Desbenoit, Associate Dylan Allali, all Corporate/M&A Caroline Froger-Michon, Partner Aurélie Parchet, As­so­ci­ate Ca­m­ille Baumgarten, Associate Sophie Yin, all Em­ploy­ment Claire Vannini, Partner Eleni Moraïtou, Coun­sel Lilia-Ori­ana Dif, Associate Ariane Rolin, all Competition & EU  Jean-Bap­tiste Thiénot, Partner Anaïs Arnal, Associate, both Intellectual Property Laurine Mayer, Associate, TMC Alexandre Chazot, Counsel, Banking & Fin­ance  Thi­erry Granier, Partner Renaud Grob, Partner, both Tax Arnaud Valverde, Senior Associate, Real Estate Olivier Kuhn, Partner Cécile Rebiffé, Counsel Mylène Garrouste, all Dispute Res­ol­u­tion Kawthar Ben Khelil, Coun­sel Jean-Pierre Malili, Associate, both Public law/In­fra­struc­ture CMS Italy Massimo Trentino, Partner, Corporate/M&A Maria Letizia Patania, Partner, Lifescience & Healthcare Gian Marco Lettieri, Senior Associate, Employment & Pensions Giulio Poggioli, Counsel Valerio Giuseppe Daniele, As­so­ci­ate Francesca Durante, Junior As­so­ci­ate  Arianna Toccaceli, Junior Associate, all Banking & Finance CMS Luxembourg Gérard Maitrejean, Partner Miruna Poenaru, Coun­sel Max­imili­an Helfgen, Associate, all Corporate/M&A CMS UK Jack Letson, Partner Lindsay McAllister, Associate, both Corporate/M&A David Dennis, Partner, Commercial CMS Netherlands Pieter van Duijvenvoorde, Partner Robert Jong, both Corporate/M&A Nigel Henssen Fleur van Assendelft de Coningh, both Employment Edmon Oude Elferink, Partner Marijke van der Vossen, both Antitrust, Competition & Trade CMS Serbia Radivoje Petrikić, Partner Mila Drljević, both Corporate/M&A CMS Austria Dieter Zandler, Partner Vanessa Horaceck, both Competition & EU CMS Ukraine Maria Orlyk, Partner Diana Valyeyeva CMS Turkiye Döne Yalçın, Partner Arcan Kemahlı,  Sa­ba­hat­tin Öztemiz Taner ElmasPress Con­tact presse@cms-hs. com
30/01/2024
What’s in a name? Updated EMA guideline on naming medicinal products processed...
The updated EMA Guideline on the acceptability of names for human medicinal products processed through the centralised procedure was adopted by CHMP in December 2023 and came into effect on 1 January...
16/01/2024
CMS advises listed mobility solutions specialist Össur on acquisition of...
Frankfurt/Main – Össur, Nasdaq Copenhagen listed leading global provider of innovative mobility solutions, acquired all shares of privately owned Fior & Gentz, a Germany based leading European manufacturer of lower limb neuro orthotic components. Fior & Gentz develops and distributes knee and ankle orthotic joints to create innovative custom-made orthotic solutions for patients with gait impairments due to neurological conditions. The acquisition of Fior & Gentz represents an attractive opportunity for Össur to enter the fast-growing neuro orthotics market. The transaction volume amounts to around EUR 100 million plus an earn-out of up to EUR 20 million. The payment consists of cash as well as of newly issued, listed shares of Icelandic Össur hf. to the sellers of Fior & Gentz. An international CMS team led by Dr Heike Wagner and Dr Tobias Kilian advised Össur comprehensively on all legal aspects also in connection with this transaction. CMS Germany Dr Heike Wagner, Partner Dr Tobias Kilian, Of Counsel, both Lead Dr Reiner Thieme, As­so­ci­ate Nath­alie Amrhen, Associate, all Corporate / M&A Jörg Schrade, Partner Eduard Kosavtsev, Senior Associate, both Tax Dr Roland Wiring, Partner Dr Siham Hidar, Senior Associate  Noah Rodenkirchen, Associate, all Regulatory & Lifesciences Dr Stefan Lehr, Partner, Antitrust, Competition & Trade Dr Dirk Smielick, Principal Counsel, IP Prof Dr Malte Grützmacher, Partner, IT Dr Boris Alles, Partner Dela Herr, Associate, both Labor, Employment & Pensions  Dr Franz Maurer, Counsel Wiebke Westermann, Associate, both Real Estate & Public CMS Netherlands Roman Tarlavski, Part­ner Mar­cel­lina Rietvelt, Associate, both Corporate / M&A Martijn van der Bie, Partner Gieneke van Nierop, Counsel, both Corporate / Notaries CMS Norway Nicolas Jorn Brunet, Partner Tuva Svare, Associate, both Corporate / M&A Henrik Nordling, Partner, Antitrust, Competition & TradePress Con­tact presse@cms-hs. com
08/01/2024
Adapting to the new EU Data Act: implications for medical devices and other...
In recent years, the European Commission developed a European data strategy, which aims to create a single European market in which data can circulate freely. As the European Commission has emphasized...
03/01/2024
CMS Life Sciences & Healthcare Global Brochure
With big deals fuelling record levels of M&A activity, a steady stream of innovative and disruptive technologies, new and increasingly complex regulatory challenges and a thriving start-up community...
18/12/2023
Digital health apps and telemedicine in Germany
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? Software as a medical deviceSoftware within digital health...
Comparable
15/12/2023
Grate news for Grana Padano: logo granted cumulative protection in EU
Collective marks and protected designations of origin (PDOs) have different functions and confer different levels of protection. While the function of a collective mark is to indicate membership of an...
08/12/2023
COP28: Global Health Under the Spotlight
Health took centre stage at the first ever ‘Health Day’ at COP28 on 3 December. The program focused the attention of world leaders on the profound public health-related issues stemming from climate...
08/11/2023
CMS Life Sciences Vital Signs, Winter 2023
2023 has seen some significant legal developments impacting the life sciences industry, and as we look ahead to 2024, there are several important developments which we would like to keep our clients informed...
08/11/2023
Cannabis law and legislation in Germany
Medical use The legalisation of cannabis for medical use took place in 2017. It is therefore permitted to grow, sell and import cannabis for medical use in Germany. Pursuant to the German Narcotics Act...
28/09/2023
EP Case Law in Brief: Erroneous Disclosures
“Mistakes in a document do not in themselves constitute prior art such as to prevent the grant of a patent.”So begins section I.C. 4.9 of the Case Law of the Boards of Appeal. This statement, and...
31/08/2023
Deep sea mining: navigating in murky waters
On 9 July 2023, the latest deadline for finalising the draft exploitation regulations for deep sea mining in international waters expired without agree­ment.1 This deadline resulted from a letter from...